Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhonghua Fu

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Frontiers in Physiology|September 8, 2025
Fu's subcutaneous needling facilitates muscle repair by regulating mitochondrial homeostasis in rat with chronic peripheral nervous painPo-En Chiu, Zhonghua Fu, Hung-Chuan Pan, et al.
Frontiers in Oncology|June 9, 2025
CAR T- cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patientsRui Liu, Fan Yang, Lixia Ma, et al.
Cytotherapy|May 9, 2025
Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphomaFei Xue, Rui Liu, Zhonghua Fu, et al.
Frontiers in Medicine|January 29, 2026
CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrierDanyang Li, Rui Liu, Zhonghua Fu, et al.
Discover Oncology|May 20, 2026
Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHLDanyang Li, Zhonghua Fu, Rui Liu, et al.
Transplantation and Cellular Therapy|August 1, 2025
CD20CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19CAR-TFei Xue, Huazhou Shi, Rui Liu, et al.
Annals of Hematology|July 8, 2026
Baseline immunonutritional status drives CAR T-cell efficacy, survival, and safety in R/R lymphoma: validation of a pre-lymphodepletion PNI thresholdNa Zhang, Fan Yang, Rui Liu, et al.
Frontiers in Immunology|February 23, 2026
Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort studyYuelu Guo, Lixia Ma, Fan Yang, et al.
Frontiers in Immunology|June 19, 2026
Impact of <i>TP53</i> mutations on survival outcomes in the CAR-T era of large B-cell lymphomaRui Liu, Zhonghua Fu, Fan Yang, et al.
Frontiers in Immunology|March 13, 2025
Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical studyDanyang Li, Rui Liu, Zhonghua Fu, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Frontiers in Physiology|September 8, 2025
Fu's subcutaneous needling facilitates muscle repair by regulating mitochondrial homeostasis in rat with chronic peripheral nervous painPo-En Chiu, Zhonghua Fu, Hung-Chuan Pan, et al.
Frontiers in Oncology|June 9, 2025
CAR T- cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patientsRui Liu, Fan Yang, Lixia Ma, et al.
Cytotherapy|May 9, 2025
Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphomaFei Xue, Rui Liu, Zhonghua Fu, et al.
Frontiers in Medicine|January 29, 2026
CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrierDanyang Li, Rui Liu, Zhonghua Fu, et al.
Discover Oncology|May 20, 2026
Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHLDanyang Li, Zhonghua Fu, Rui Liu, et al.
Transplantation and Cellular Therapy|August 1, 2025
CD20CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19CAR-TFei Xue, Huazhou Shi, Rui Liu, et al.
Annals of Hematology|July 8, 2026
Baseline immunonutritional status drives CAR T-cell efficacy, survival, and safety in R/R lymphoma: validation of a pre-lymphodepletion PNI thresholdNa Zhang, Fan Yang, Rui Liu, et al.
Frontiers in Immunology|February 23, 2026
Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort studyYuelu Guo, Lixia Ma, Fan Yang, et al.
Frontiers in Immunology|June 19, 2026
Impact of <i>TP53</i> mutations on survival outcomes in the CAR-T era of large B-cell lymphomaRui Liu, Zhonghua Fu, Fan Yang, et al.
Frontiers in Immunology|March 13, 2025
Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical studyDanyang Li, Rui Liu, Zhonghua Fu, et al.
Pageof 6